AzTrials
AzTrials

Chronic Low Back PainPhase 3NCT00325949

A Study of Pain Relief in Low Back Pain

A Phase 3 study testing Extended release hydrocodone and acetaminophen (Vicodin CR) and hydrocodone/acetaminophen extended release (Vicodin CR) in people with Chronic Low Back Pain, run by Abbott at 63 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a study of the safety and pain-relieving ability of extended release hydrocodone and acetaminophen tablets in patients with moderate to severe low back pain Read more about this study

Who is it for?
Ages 21 to 75 years
Conditions the study is for
Chronic Low Back Pain
What is being tested?
Extended release hydrocodone and acetaminophen (Vicodin CR) and hydrocodone/acetaminophen extended release (Vicodin CR)
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
770 participants
Where
63 sitesUnited States
Study dates
May 2006to Jun 2007
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Males and females, ages 21-75 years
  • If female, must be of non-child bearing potential or practicing birth control
  • Has a history of chronic low back pain for at least 6 months
  • Requires medication for the management of the chronic low back pain
  • Has sufficient pain to justify the use of around-the-clock opioids

Who cannot join

  • Is associated with any currently ongoing research study, or has previously participated in a Vicodin CR study
  • Is allergic or has had a serious reaction to hydrocodone, other opioids, or acetaminophen
  • Cannot discontinue pain medications, even for the short time prior to the study start
  • Has any clinically significant illness or recent injury, or has any significant laboratory abnormality, or has recently had major surgery, or plans to have surgery
  • Has a history of gastric bypass surgery or preexisting gastrointestinal narrowing, or history of diseases that may narrow the gastrointestinal tract
  • Has a history of malnutrition or starvation
Show all 14Show fewer
  • Has a history of drug (licit or illicit) or alcohol abuse or addiction, or consumes more than 4 alcoholic drinks per day
  • Has a history of a major depressive episode within the past 2 years, or requires treatment with certain drugs for depression, or has a history of major psychiatric disorder
  • Is a pregnant or breastfeeding woman
  • Is incapacitated, bedridden, or confined to a wheelchair
  • Has initiated any new therapy or medication for chronic low back pain within 1 month of screening
  • Has had surgery, certain types of low back procedures, injured, or received certain medications for chronic low back pain within a certain specified time frame
  • Has back pain due to or associated with certain types of conditions
  • Has other conditions that may cause pain, such as rheumatoid arthritis, gout, or fibromyalgia

Trial locations and contacts

63 sites in 1 country.

63 sites in 1 country

United States63 sites
  • Site Ref # / Investigator 1975

    Atlanta, Georgia, 30328

  • Site Ref # / Investigator 2217

    Austin, Texas, 78705

  • Site Ref # / Investigator 3420

    Biloxi, Mississippi, 39531

  • Site Ref # / Investigator 2603

    Brockton, Massachusetts, 02301

  • Site Ref # / Investigator 1992

    Buena Park, California, 90620

  • Site Ref # / Investigator 2607

    Bulverde, Texas, 78163

  • Site Ref # / Investigator 1993

    Burbank, California, 91505

  • Site Ref # / Investigator 1985

    Chicago, Illinois, 60610

  • Site Ref # / Investigator 2218

    Cincinnati, Ohio, 45227

  • Site Ref # / Investigator 1995

    Cincinnati, Ohio, 45242

  • Site Ref # / Investigator 1987

    Cincinnati, Ohio, 45245

  • Site Ref # / Investigator 2208

    Clearwater, Florida, 33756

  • Site Ref # / Investigator 1984

    Cordova, Tennessee, 38018

  • Site Ref # / Investigator 2137

    Cranston, Rhode Island, 02920

  • Site Ref # / Investigator 2590

    Dallas, Texas, 75251

  • Site Ref # / Investigator 1991

    Decatur, Georgia, 30033

  • Site Ref # / Investigator 2210

    DeLand, Florida, 32720

  • Site Ref # / Investigator 2157

    Denver, Colorado, 80209

  • Site Ref # / Investigator 2215

    Downingtown, Pennsylvania, 19335

  • Site Ref # / Investigator 2579

    Duncansville, Pennsylvania, 16635

  • Site Ref # / Investigator 1978

    Evansville, Indiana, 47714

  • Site Ref # / Investigator 2219

    Fair Oaks, California, 95628

  • Site Ref # / Investigator 2556

    Florissant, Missouri, 63031

  • Site Ref # / Investigator 2221

    Greer, South Carolina, 29651

  • Site Ref # / Investigator 2207

    Hollywood, Florida, 33023

  • Site Ref # / Investigator 2216

    Hueytown, Alabama, 35023

  • Site Ref # / Investigator 2117

    Killeen, Texas, 76543

  • Site Ref # / Investigator 3421

    Las Vegas, Nevada, 89106

  • Site Ref # / Investigator 2206

    Las Vegas, Nevada, 89123

  • Site Ref # / Investigator 1989

    Los Gatos, California, 95032

  • Site Ref # / Investigator 2213

    Mechanicsburg, Pennsylvania, 17055

  • Site Ref # / Investigator 2209

    Metairie, Louisiana, 70006

  • Site Ref # / Investigator 2204

    Miami, Florida, 33156

  • Site Ref # / Investigator 2205

    Miami, Florida, 33186

  • Site Ref # / Investigator 1982

    Missoula, Montana, 59802

  • Site Ref # / Investigator 2604

    Nederland, Texas, 77627

  • Site Ref # / Investigator 1973

    New York, New York, 10022

  • Site Ref # / Investigator 2211

    Oklahoma City, Oklahoma, 73103

  • Site Ref # / Investigator 2214

    Oldsmar, Florida, 34677

  • Site Ref # / Investigator 1986

    Omaha, Nebraska, 68134

  • Site Ref # / Investigator 2203

    Pasadena, Maryland, 21122

  • Site Ref # / Investigator 2605

    Phoenix, Arizona, 85023

  • Site Ref # / Investigator 1990

    Phoenix, Arizona, 85029

  • Site Ref # / Investigator 2135

    Plantation, Florida, 33324

  • Site Ref # / Investigator 2580

    Prairie Village, Kansas, 66206

  • Site Ref # / Investigator 1983

    Raleigh, North Carolina, 27609

  • Site Ref # / Investigator 2606

    Raleigh, North Carolina, 27612

  • Site Ref # / Investigator 1979

    Richardson, Texas, 75080

  • Site Ref # / Investigator 2212

    San Angelo, Texas, 76904

  • Site Ref # / Investigator 1981

    San Antonio, Texas, 78127

  • Site Ref # / Investigator 2220

    San Antonio, Texas, 78209

  • Site Ref # / Investigator 2608

    San Antonio, Texas, 78218

  • Site Ref # / Investigator 1976

    Shreveport, Louisiana, 71103

  • Site Ref # / Investigator 1980

    St Louis, Missouri, 63141

  • Site Ref # / Investigator 1974

    Tempe, Arizona, 85282

  • Site Ref # / Investigator 1994

    Trumbull, Connecticut, 06611

  • Site Ref # / Investigator 1977

    Tucson, Arizona, 85741

  • Site Ref # / Investigator 2158

    Virginia Beach, Virginia, 23454

  • Site Ref # / Investigator 2156

    Wellesley Hills, Massachusetts, 02481-2106

  • Site Ref # / Investigator 1988

    West Des Moines, Iowa, 50265

  • Site Ref # / Investigator 2134

    West Palm Beach, Florida, 33409-3509

  • Site Ref # / Investigator 2578

    Williamsville, New York, 14221

  • Site Ref # / Investigator 5161

    Winston-Salem, North Carolina, 27103

Other trials in United States

About this study

Official title: A Phase 3, Open-Label Period Followed By a Randomized, Double-Blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) Compared to Placebo in Subjects With Chronic Low Back Pain

This is a study of the safety and pain-relieving ability of extended release hydrocodone and acetaminophen tablets in patients with moderate to severe low back pain

Being tested
Extended release hydrocodone and acetaminophen (Vicodin CR), hydrocodone/acetaminophen extended release (Vicodin CR), placebo

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Extended release hydrocodone and acetaminophen (Vicodin CR)Drug

    Also called hydrocodone / acetaminophen extended release

    2 tablets BID

  • hydrocodone/acetaminophen extended release (Vicodin CR)Drug

    Also called hydrocodone/acetaminophen extended release

    1 tablet BID

  • placeboDrug

    2 tablets BID

Study groups in NCT00325949
Study groupRoleWhat they receive
arm label (1) hydrocodone/acetaminophen extended releaseExperimentalNot described
Receives: Drug: Extended release hydrocodone and acetaminophen (Vicodin CR)
arm label (2) hydrocodone/acetaminophen extended releaseExperimentalNot described
Receives: Drug: hydrocodone/acetaminophen extended release (Vicodin CR)
Arm label (3) placeboPlacebo comparatorNot described
Receives: Drug: placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain Intensity Difference from randomization baseline to each subject's final assessment

    Pain intensity difference assessed by the Chronic Low Back Pain Intensity Score (100mm Visual Analog Scale)

    Measured: 12 Weeks

Secondary outcomes (4)
  1. Time to withdrawal due to lack of efficacy during the Double-blind Maintenance Period

  2. Pain Intensity Difference from randomization baseline to each scheduled assessment

  3. Global Assessments of Study Drug and Back Pain Status

  4. Roland-Morris Disability Questionnaire

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 May 2006 (estimated)
  2. Study startMay 2006
  3. Primary completionMay 2007
  4. Study completionJun 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Enrolment
770 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00325949
Sponsor's protocol ID
M05-790
Status last verified
Jul 2011
First submitted
11 May 2006
Last updated
25 Jul 2011
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Extended release hydrocodone and acetaminophen (Vicodin CR) and hydrocodone/acetaminophen extended release (Vicodin CR) in people with Chronic Low Back Pain, run by Abbott at 63 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Jul 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 63 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain Intensity Difference from randomization baseline to each subject's final assessment (time frame: 12 Weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jul 2011.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in